CB 1001

Drug Profile

CB 1001

Alternative Names: Cancer vaccine - Cosmo Pharmaceuticals; CB-10-01; TLI

Latest Information Update: 04 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 08 Jul 2009 Phase-II development is ongoing in USA
  • 03 May 2005 Phase-II clinical trials in Prostate cancer in USA (Infusion)
  • 09 Jun 2004 Preclinical trials in Solid tumours in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top